Gao Y, Liu R, Shi J, Shan W, Zhou H, Chen Z
EBioMedicine. 2024; 112:105535.
PMID: 39740295
PMC: 11750515.
DOI: 10.1016/j.ebiom.2024.105535.
Mahmoudjafari Z, Bhatt V, Galvin J, Xue Z, Zeiser R, Locatelli F
Bone Marrow Transplant. 2024; 60(1):69-78.
PMID: 39506073
PMC: 11726446.
DOI: 10.1038/s41409-024-02445-6.
Gagliano C, Foti R, Zeppieri M, Maniaci A, Lavalle S, Tancredi G
Life (Basel). 2024; 14(10).
PMID: 39459568
PMC: 11509496.
DOI: 10.3390/life14101268.
Nguyen J, Jessri M, Costa-da-Silva A, Sharma R, Mays J, Treister N
Int J Mol Sci. 2024; 25(19).
PMID: 39408739
PMC: 11476840.
DOI: 10.3390/ijms251910411.
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(8):713-726.
PMID: 39307718
PMC: 11535560.
DOI: 10.3760/cma.j.cn121090-20240611-00217.
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
Wei Y, Qian K, Le N, Wang L, Li F, Luan S
Ann Hematol. 2024; 103(11):4707-4719.
PMID: 39243311
DOI: 10.1007/s00277-024-05972-w.
Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease-an analysis from transplant centers across Europe.
Langer R, Lelas A, Rittenschober M, Piekarska A, Sadowska-Klasa A, Sabol I
Front Transplant. 2024; 3:1332181.
PMID: 38993773
PMC: 11235324.
DOI: 10.3389/frtra.2024.1332181.
Associations between acute and chronic graft-versus-host disease.
Tamaki M, Akahoshi Y, Inamoto Y, Morita K, Uchida N, Doki N
Blood Adv. 2024; 8(16):4250-4261.
PMID: 38985337
PMC: 11372601.
DOI: 10.1182/bloodadvances.2024013442.
Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation.
Pidala J, Onstad L, Baumrin E, Carpenter P, Cutler C, Arai S
Blood Adv. 2024; 8(17):4651-4657.
PMID: 38885484
PMC: 11402177.
DOI: 10.1182/bloodadvances.2024013233.
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
Nikiforow S, Whangbo J, Reshef R, Tsai D, Bunin N, Abu-Arja R
Blood Adv. 2024; 8(12):3001-3012.
PMID: 38625984
PMC: 11215195.
DOI: 10.1182/bloodadvances.2023011626.
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores.
Rozmus J, Levine J, Schultz K
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):149-154.
PMID: 38066854
PMC: 10727102.
DOI: 10.1182/hematology.2023000425.
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J
Bone Marrow Transplant. 2023; 59(1):66-75.
PMID: 37898725
DOI: 10.1038/s41409-023-02142-w.
[Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
Du J, Wang H, Dou L, Wang N, Li F, Jin X
Zhonghua Xue Ye Xue Za Zhi. 2023; 44(8):660-666.
PMID: 37803840
PMC: 10520230.
DOI: 10.3760/cma.j.issn.0253-2727.2023.08.008.
Red cell distribution width as a new prognostic biomarker in refractory chronic graft--host disease.
Schulz E, Pirsl F, Holtzman N, Beshensky D, Cowen E, Mitchell S
Haematologica. 2023; 109(1):298-302.
PMID: 37584292
PMC: 10772496.
DOI: 10.3324/haematol.2023.283646.
Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy.
Fuji S, Hakoda A, Kanda J, Fukuda T, Doki N, Katayama Y
Bone Marrow Transplant. 2023; 58(11):1257-1259.
PMID: 37550450
DOI: 10.1038/s41409-023-02076-3.
Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.
Tappeiner C, Heiligenhaus A, Halter J, Miserocchi E, Bandello F, Goldblum D
Front Med (Lausanne). 2023; 10:1133381.
PMID: 36891189
PMC: 9987249.
DOI: 10.3389/fmed.2023.1133381.
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society....
Srour M, Alsuliman T, Labreuche J, Bulabois C, Chevallier P, Daguindau E
Bone Marrow Transplant. 2023; 58(4):401-406.
PMID: 36624161
DOI: 10.1038/s41409-022-01898-x.
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
Miklos D, Zaid M, Cooney J, Albring J, Flowers M, Skarbnik A
J Clin Oncol. 2023; 41(10):1876-1887.
PMID: 36608310
PMC: 10082299.
DOI: 10.1200/JCO.22.00509.
Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.
Baumrin E, Loren A, Falk S, Mays J, Cowen E
J Am Acad Dermatol. 2022; 90(1):1-16.
PMID: 36572065
PMC: 10287844.
DOI: 10.1016/j.jaad.2022.12.024.
A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.
Johnson L, Oh U, Rothen M, Sroussi H, Dean D, Lloid C
J Dent Hyg. 2022; 96(2):6-17.
PMID: 35418491
PMC: 10392699.